Index

Page numbers followed by b, indicate boxes; f, figures; and t, tables.

AAA. See Aromatic amino acids
AAFCO. See Association of American Feed Control Officials
Absorption, age-related changes in, 87
Acetabulum, ossification of, 143
Acid-base balance, in chronic kidney disease, 256
Aciduria, as calcium oxalate urolith risk factor, 271
Activity-related energy expenditure, 25
Acute renal failure (ARF), 260–262
ACVN (American College of Veterinary Nutrition), 7
Adenosine triphosphate (ATP), 9, 50
Adequate intake, defined, 21
Ad libitum feeding, 80
ADMA (asymmetric dimethylarginine), 258
Adverse food reactions
  gastrointestinal disease and, 200–201, 201t
  renal disease concurrent with, 259
Advice, nutritional
  for healthy patients, 6
  revenue from, 5–7
  for unhealthy patients, 6–7
Aerophagia, 207
Aging, physiological changes in, 86–88
  behavior, 88
  digestion and absorption, 87
  energy requirement, 86–87
  immune response, 87–88
  integument and musculoskeletal system, 87
  renal system, 87
  sensory, 88
AGRICOLA, 64
Alaskan Malamutes, zinc responsive dermatosis in, 159
Alimentary hypercalcitoninism, 135–137, 136f–138f
Alkalization therapy, in chronic kidney disease, 256
Allopurinol, for urate uroliths, 277, 279
Alopecia
  in protein deficiency, 157–158
  in zinc deficiency, 159
Alpha-linoleic acid deficiency, 158
American College of Veterinary Nutrition (ACVN), 7
Amino acids
  in cancer diet, 320–322
  D- and L-, 11
  deficiency
    signs, 15–16
    testing, 15–16
  essential, 11
  in home-prepared diets, 101–102
  intravenous administration of, 165–166
  limiting, 11
  in liver disease, 236–237
  in superficial necrolytic dermatitis, 163–166, 163f
Amino acid solutions
  for acute renal failure, 262
  for parenteral nutrition, 358, 359f
Aminosyn IV solution, 165–166
Aminotransferases, 75
Ammonium urate uroliths, 276–279, 277f–279f
Amylase inhibitors, as weight reduction aid, 118t
Anagen defluxion, 157–158
Anemia, in inflammatory bowel disease, 194
Animal Dietary Supplement, defined, 57–58
Anorexia, in cardiac disease, 304, 306
Antigen presenting cells (APCs), 181
Antimicrobials, for portosystemic encephalopathy, 246
Antioxidants
  in cancer diet, 322–324
  for canine cognitive dysfunction disorder, 89
  for chronic kidney disease, 257
  for congestive heart failure, 307
  for copper hepatotoxicity, 242
  deficiency in inflammatory bowel disease, 195
  for exercising dog, 54–55
  for inflammatory bowel disease therapy, 197
  for osteoarthritis, 149
  supplementation for hepatic lipidosis, 241
  supplementation for older pets, 89
APCs (antigen presenting cells), 181
Appetite stimulants, in chronic kidney disease, 259
Arachidonic acid deficiency, 16, 158
  in home-prepared diets, 102
  overview, 12
ARF (acute renal failure), 260–262
Arginine
  asymmetric dimethylarginine competition with L-arginine, 258
  cat requirement for, 75
  deficiency
    encephalopathy from, 245
    symptoms, 15
  dog requirement for, 76
  in enteral feeding, 342–343
  immunity enhancement by, 185–186
  for inflammatory bowel disease therapy, 196–197
Arginine (cont’d)
supplementation in cancer, 321–322
in congestive heart failure, 308
Aromatic amino acids (AAA)
increase in liver disease, 236, 236t
ratio to branch chain amino acids
(BCAA:AAA ratio), 163
Arterial thromboembolism (ATE), 301, 302
Ascites, 246–247
Association of American Feed Control
Officials (AAFCO) described, 57
dietary supplements and, 60–62
feeding trials, 81
“natural” defined by, 97
nutrient requirements from, 20–21
Official Publication, 69, 71
“organic” defined by, 97
pet food labels and, 69–71
Asymmetric dimethylarginine (ADMA),
Body condition, in cats and dogs with
Board-certified veterinary nutritionist, 7
Bland diet, for acute gastroenteritis, 183
Bisphenol A, 296
Biotin
deficiency, 19, 162
supplementation for skin disease
management, 171
Bisphenol A, 296
Bland diet, for acute gastroenteritis, 183
Board-certified veterinary nutritionist, 7
Body condition, in cats and dogs with
cancer, 316
Body condition scoring
description of, 111–112
9-point system for cats, 113t, 115f
9-point system for dogs, 112t, 114f
Body weight
calculating energy requirements from, 31–41
energy expenditure and, 33–34
Body weight management, 109–121
accounting of caloric intake, 113, 116
body condition scoring
description of, 111–112
9-point system for cats, 113t, 115f
9-point system for dogs, 112t, 114f
dietary history, 113, 116, 116b
health consequences of weight excess, 110–111
overview, 109–110
physical examination, 113
risk factors for weight gain, 112–113
targeting optional weight, 111
weight loss plan adjustment, 120–121, 121t
weight loss plan assessment, 119–120
safety and efficacy, 120
time to achieve goal, 119b
weight loss plan formulation, 116–119,
117b, 118t–119t
design considerations, 119t
dietary considerations, 117–118
exercise, 119
nutrients and dietary supplements, 118t
steps, 117b
tailoring program to patient, 119
Bomb calorimetry, 27
Bonding activity, feeding as, 120–121
Borbyrgymus, 205–206
Bottle feeding, 83
Bowel rest, 183
Branch chain amino acids (BCAAs)
increase in liver disease, 236–237, 236t
ratio to aromatic amino acids
(BCAA:AAA ratio), 163
Brody equation, 34
Bull Terriers, copper hepatotoxicity
in, 241–242, 241f
Behavioral changes, in older pets, 88
Belch reflex, 192
Beta-glucans, 177t
BHA (butylated hydroxyanisole), 97
BHT (butylated hydroxytoluene), 97
Bicarbonaturia, in Fanconi Syndrome, 263
Bile salt-induced diarrhea, 202
Biological value, 12
Biotin
deficiency, 19, 162
supplementation for skin disease
management, 171
Cutaneous adverse food
reaction, 129–130, 136–137
Calcitriol, 126–127, 253–254
Calcium
in bone, 125–127, 126t–128t
deficiency
orthopedic disease and, 129–134,
130t, 131f–133f, 132t
symptoms, 16
excess, orthopedic disease and, 135–137, 136f–138f
hormonal regulation of, 127–129
supplementation during gestation and
lactation, 83
Calcium oxalate uroliths, 270–274, 270f
Calculus, 188–192
Caloric distribution calculation, 72
Calorie content estimating, 72
on pet food label, 71–72
Calories
amount to feed, determining, 76
defined, 23
sources in cancer, 319–320
Calorimetry
bomb, 27
direct, 31
indirect respiratory, 31–33
Calorimetry chamber method, of indirect
respiration calorimetry, 33
Cancer. See also Oncological diseases
cachexia in, 315–316
metabolizable energy calculation, 42
Canine cognitive dysfunction disorder, 89
Carbohydrates. See also Fiber
in cancer diet, 319–320
in diabetes mellitus, 290–291
during gestation and lactation in dogs,
305f
heat equivalents, 33
in home-prepared diets, 102
metabolic alterations in liver disease,
235–236
metabolizing enzymes in cats, 75
in parenteral nutrition, 359t, 360–361
respiratory quotient, 33
role in diet, 12–13
soluble, 290–291
Cardiac cachexia, 304, 305f, 306
Cardiovascular disease, 301–311
feeding cats with cardiac disease, 301–303
dilated cardiomyopathy, 301–302
hypertension, 303
hypertrophic cardiomyopathy, 302–303
feeding dogs with cardiac disease, 303–309
antioxidants, 307
arginine, 308
asymptomatic disease, 303–304
cardiac cachexia, 304, 305f, 306
dilated cardiomyopathy, 305f, 308–309
magnesium, 307
mild to moderate congestive heart failure, 304–308, 305f
n-3 fatty acids, 306–307
potassium, 307
severe or refractory congestive heart failure, 308
sodium, 307
general nutritional issues, 310–311
prevalence of, 301
Carnitine
deficiency in canine cardiomyopathy, 309
for hepatic lipidosis management, 240
supplementation for dilated cardiomyopathy, 309
as weight reduction aid, 118t
Carnivores, cats as, 75
Catabolic state in uremia, 261–262
Carnitine
dietary supplements and, 59–63
described, 58
unique metabolics, 11
pansteatitis in, 161–162
Cholecystokinin (CCK), 175–177, 221, 222f
Cholesterol, in hyperlipidemia, 294–295
Cholestyramine, 202
Choline deficiency, 19–20
Chondroitin sulphate, 148–149, 150t
Chromium
supplementation in diabetes mellitus, 293
as weight reduction aid, 118t
Chronic valvular disease, 303
Chylomicrons, 294–295
Chylothorax, parenteral nutrition for, 356
Chymes, 189–190
CHF. See Congestive heart failure
Chloride deficiency, 17
Cholecalciferol (vitamin D), 127–129
Cholecystokinin (CCK), 175–177, 221, 222f
Cholesterol, in hyperlipidemia, 294–295
Cholesterymine, 202
Choline deficiency, 19–20
Chondroitin sulphate, 148–149, 150t
Chromium
supplementation in diabetes mellitus, 293
as weight reduction aid, 118t
Chronic valvular disease, 303
Chylomicrons, 294–295
Chylothorax, parenteral nutrition for, 356
Citrate, for calcium oxalate prevention, 238–239f
Congestive heart failure (CHF)
for acute nonspecific gastroenteritis, 188
for calcium oxalate urolithiasis, 274
for cancer, 319
market segments, 98
for pancreatitis, 227
periodontal disease and, 188–189
for struvite uroliths, 276
terminology, 97
types of foods
dry, 95
moist, 95–96
raw, 96
semi-moist, 96
Compounding, parenteral nutrition, 363–365, 364f–365f
Congestive heart failure (CHF)
mild to moderate, 304–308, 305f
severe or refractory, 308
Constipation, 204–205
Copper chelators, 242
deficiency
skin disease and, 158t, 161
symptoms, 17
pharmacologic reduction of, 242
restriction in copper-associated hepatotoxicity, 242
Copper hepatotoxicity, 238, 241–243
antioxidants, 242
breed associations, 241, 241f
copper chelators, 242
dietary copper restriction, 242
energy, 241
milk thistle, 243
S-adenosylmethionine (SAMe), 243
vitamin E, 243
zinc, 242
Corn oil, 102
Corticosteroids, for osteoarthritis, 147
COX1 inhibitors, 147–148
COX2 inhibitors, 147–148
CPN (central parenteral nutrition), 261–262, 357
Creatine, 55
Crude fiber. See also Fiber
gross energy value of, 28
metabolizable energy content of food calculations and, 30–31
Crystals, urinary. See Urolithiasis
Cutaneous adverse food reaction (CAFR), 166–169
clinical signs, 167, 167f
description of, 166–167
diagnosis and treatment, 167–169, 170f
Cutaneous xanthomatosis, 169
CVM. See Center for Veterinary Medicine
Cyanuric acid, 12
Cysteine, 157
Cystine, as sparing nutrient, 10
Cystine uroliths, 280–281, 280f–281f
Cystitis, idiopathic, 282–283
Dachshunds, cystine uroliths in, 280
DAG oil (diacylglycerol oil), as weight reduction aid, 118t
Dalmatian
copper hepatotoxicity in, 241
urate uroliths in, 276, 277f
DCM. See Dilated cardiomyopathy
Deficiency. See Nutritional deficiency
Dehydration, 54
Dental diets, 190
Deoxycholic acid (DCA), 178
Dextrose solutions, for parenteral nutrition, 359, 360–361
DHA. See Docosahexaenoic acid
DHEA (dehydroepiandrosterone), as weight reduction aid, 118t
Diabetes mellitus, 289–293
feeding recommendations and assessment, 293
food type for, 293
insulin-dependent (IDDM), 289, 291, 293
Deoxycholic acid (DCA), 178
Dextrose solutions, for parenteral nutrition, 359, 360–361
DHA. See Docosahexaenoic acid
DHEA (dehydroepiandrosterone), as weight reduction aid, 118t
Diabetes mellitus, 289–293
feeding recommendations and assessment, 293
food type for, 293
insulin-dependent (IDDM), 289, 291, 293
...
Diabetes mellitus (cont’d)

- non-insulin-dependent (NIDDM), 289–290
- nutritional factors
  - energy, 289–290
  - fat, 292
  - fiber, 291–292
  - minerals and vitamins, 293
  - protein, 292–293
  - soluble carbohydrates, 290–291
  - water, 289
  - obesity as risk factor, 110, 290

Diarrhea

- bile salt-induced, 202
- in enterally fed patients, 346
- food responsive, 200–201
- idiopathic large bowel, 204
- osmotic, 184

Dietary supplements, 57–66

- overview, 57
- recommendation, 5
- regulation of, 57–63
  - animal products, 60–63
  - definitions, 57–58
- Dietary Supplement Health and Education Act of 1994 (DSHEA), 58–60

- Dietary supplements, 57–66
  - in cancer, 324
  - defined, 58
  - ergogenic nutrients, 55
  - during gestation and lactation, 83
  - information sources, 66, 66t
  - for older pets, 89
  - overview, 57
  - recommending, 5
  - regulation of, 57–63
    - animal products, 60–63
    - definitions, 57–58
- Dietary Supplement Health and Education Act of 1994 (DSHEA), 58–60
- state regulation, 60–62
- use in practice, 63–65
  - assessment of commercial source, 64–65
  - assessment of evidence, 63–64
  - assessment of need, 63
  - assessment of outcomes, 65
  - guidelines for evaluation, 63–65
  - steps for evaluation, 65t

Diet history

- checklist, 116b
  - for chronic pancreatitis management, 227
  - in elimination diet trial, 167–168
  - energy requirement determination and, 26
  - for weight management, 113, 116
- Diet history form, 77f–79f
- Diet-induced thermogenesis. See Heat increment

Digestibility, 187

Digestible energy

- calculation of, 29
- defined, 24

Digestion, age-related changes in, 87

Digestive tract, age-related changes in, 87

Digestive tract, age-related changes in, 87

Digestion, age-related changes in, 87

Digestible energy

Dietary anion gap, 143

Dichloroacetic acid, 55

Diarrhea

- defined, 24
- calculation of, 29

Diet-induced thermogenesis.

Diet history form, 77f–79f

Diet history

Dietary supplements, 57–66

- Dietary Supplement Health and Education Act of 1994 (DSHEA), 58–60

Dogs

- cardiovascular disease, 303–309
- cutaneous adverse food reaction (CAFR), 167
- feeding guidelines
  - for adults, 85
  - for gestation and lactation, 82–83
  - for growth in orphans, 83–84
  - neuring, effect of, 84–85
  - for seniors, 85–90
  - from weaning to adult, 84–85
  - 9-point body condition scoring system for, 112t, 114f
- nutritional requirements, 76
- Dorsal acetabular rim, 143
- Doubly labeled water method, of indirect respiration calorimetry, 33
- D-penicillamine, for copper hepatotoxicity, 241
- Drug, defined, 58
- Dry food, 95
- Dry matter basis, converting nutrient levels to, 73
- DSHEA (Dietary Supplement Health and Education Act of 1994), 58–60

Eclampsia, 73

ECVCN (European College of Veterinary Comparative Nutrition), 7

EFAs. See Essential fatty acids

Eicosapentaenoic acid (EPA)

- for cancer, 322
- for chronic kidney disease, 256
- for congestive heart failure, 306–307
- cyclooxygenase and, 198
- deficiency, 158
- in home-prepared diet, 102
- for osteoarthritis, 149

Elbow dysplasia, 141–142, 141f

Electrolytes

- in chronic kidney disease, 254–256
- for parenteral nutrition, 359t, 361
- parenteral nutrition complications, 368
- requirements for exercising dog, 54

Elevated feeding, 192

Elimination diet

- for adverse food reaction, 200
- for inflammatory bowel disease, 195–196
- trial for cutaneous adverse food reaction (CAFR), 167–169

Elizabethan collar, 332, 332f

Endochondral ossification, 125, 128

Endocrine diseases, 289–297

- diabetes mellitus, 289–293
- feline idiopathic hypercalcemia, 297
- hyperadrenocorticism, 296
- hyperlipidemia, 294–296
- hyperthyroidism, 296–297
- hypothyroidism, 296

Endothelium
dysfunction in renal disease, 258

Enema, butyrate, 203

Energy

- in acute renal failure, 261
- calculation of energy requirements, 343
- in cancer, 317–319
- in chronic kidney disease, 251–252
- in copper hepatotoxicity, 241
- defined, 23
- in diabetes mellitus, 289–290
- dietary content, calculating, 26–31
- in hepatic lipidosis, 239–240
- nutrition and, 9–10
- orthopedic disease management, 129
- in parenteral nutrition, 363
- requirements, 10
- terminology of metabolism, 24, 24f
- units of measurement, 23–24

Energy balance, 24

Energy basis, converting nutrient levels to, 73

Energy expenditure

- activity-related, 25
- basal, 25, 33–34
- body weight and, 33–34
- fasting, 25
- heat increment, 25
- methods of determining, 31–34
- respiratory quotient and, 32–33
- resting, 25, 34
- terminology, 25

Energy requirements

- age-related decline in, 86–88
- determining, 23–43
  - from body weight, 31–41
  - calculating energy content of diet, 26–31
from diet records or history, 26
by direct calorimetry, 31
energy requirements for growth, 38–40
energy requirements for maintenance, 34–38, 35t–37t, 38f–39f
energy requirements for pregnancy and lactation, 40–41
by indirect respiratory calorimetry, 31–33
metabolizable energy calculation, 26–31
for states of disease, 41–43, 42f
in pancreatitis management, 226
for performance and work, 48–50
terminology, 24–25
English bulldogs
cystine uroliths in, 280, 280f
urate uroliths in, 276
English cocker spaniels, struvite uroliths
in, 275
Enteral nutrition, 329–348
beginning, 336–338
calculations for feeding, 344t
in cancer, 318
complications, 343–347
gastrointestinal, 346–347
mechanical, 343–345
metabolic, 345–346
contraindications, 331
decision-making flowchart, 337
diet choices, 338
commercial diets, 338
liquid diets, 338, 339t–341t, 341–342
energy requirement calculation, 343
feeding devices, 331–336
esophagostomy feeding tubes, 332–334, 333f
gastrostomy feeding tubes, 334–335, 334f
jejunal feeding tubes, 335–336
nasoenteral feeding tubes, 332, 332f
pharyngostomy feeding tubes, 332
immunomodulating nutrients, 342–343
arginine, 342–343
glutamine, 342
reason for use, 329
transitioning patients to voluntary intake, 347
when to intervene, 330–331, 330f
Enterostomy feeding in cancer, 318
Enterostomy tubes, 336, 336f
Enzyme replacement therapy, for exocrine pancreatic insufficiency, 229
EPA. See Eicosapentaenoic acid
EPI. See Exocrine pancreatic insufficiency
Ergogenic nutrients, 55
Esophageal motility disorders, 192
Esophagitis, 192–193
Esophagostomy feeding in cancer, 318
in hepatic lipidosis, 239
in pancreatitis, 224–225, 224f
tubes, 332–334, 333f
Essential fatty acids
deficiency
skin diseases and, 158–159, 158t
zinc absorption impairment with, 160
supplementation for skin disease management, 169–171
Etretinate, 169
European College of Veterinary Comparative Nutrition (ECVCN), 7
Exercise
fatulence decrease with, 207
nutritional and energy requirements for performance, 47–55
adequate intakes, 52f
antioxidants, 54–55
ergogenic nutrients, 55
fluids and electrolytes, 54
how much to feed dogs, 47–48
for long-distance submaximal aerobic exercise, 53
for short-distance supramaximal anaerobic exercise, 53–54
time of feeding, 55
training and, 52
types of, 50–52
vitamins and minerals, 55
in weight loss program, 119
Exocrine pancreatic insufficiency (EPI), 227–230
nutritional management, 228–230
diet management, 229–230
fat content of diet, 228–229
triglycerides, 229
pathophysiology, 227–228
Face mask method, of indirect respiration calorimetry, 33
Facultative thermogenesis, 25
Fanconi Syndrome, 263
Fasting
in acute gastroenteritis, 183–184
in acute pancreatitis, 223–224
Fasting energy expenditure (fasting heat production), 25
Fat
absorption of, 176
in acute gastroenteritis, 187
balanced fat-restricted elemental diet, 200t
in cancer diet, 319–320
deficiency
signs, 16
testing, 16
in diabetes mellitus, 292
gastrointestinal tract interaction, 176–177
malabsorption
in exocrine pancreatic insufficiency, 228
in inflammatory bowel disease, 197
in short bowel syndrome, 202
in pancreatitis management, 224
in parenteral nutrition, 360
requirements in older pets, 89
restriction
in esophagitis, 193
in exocrine pancreatic insufficiency, 228–229
in hyperlipidemia, 295
for inflammatory bowel disease, 197–198
in pancreatitis, 224
for short bowel syndrome, 202
role in diet, 12
Fat-soluble vitamins
deficiency, 18
role in nutrition, 13–14
Fatty acids
deficiency
signs, 16
testing, 16
in home-prepared diets, 102
role in diet, 12
supplementation for older pets, 89
FCP (fragmented coronoid process), 141–142
FDA. See Food and Drug Administration
European Food, Drug, and Cosmetic Act (FFDCA), 58–60
Feeding
amount of food to feed, 76, 80
Diet History Form, 77f–79f
healthy dog and cat, 75–90
regimens, 80
free-choice (ad libitum), 80
portion-controlled feeding, 80
time-restricted meal feeding, 80
what to feed, 80–81
Feeding guidelines
for adults, 85
on food label, 71
for gestation and lactation, 81–83
assessment, 83
cats, 81–82
dogs, 82–83
supplementation, 83
for growth in orphans, 83–84
for seniors, 85–90
from weaning to adult, 84–85
Feeding trials, 81
Feeding tubes, 331–336
in chronic kidney disease, 259
esophagostomy, 332–334, 333f
gastrostomy, 334–335, 334f
jejunal, 335–336
nasoenteral, 332, 332f
pharyngostomy, 332
Index

Feline hyperthyroidism, 296–297
Feline idiopathic hepatic lipidosis, 238–241, 238f–239f
carnitine, 240
cyanocobalamin, 240
description, 238–239
energy, 239–240
potassium, 240
protein, 240
Feline idiopathic hypercalcemia, 297
Feline idiopathic hepatic lipidosis, 380
Feline hyperthyroidism, 296–297
Food allergy.
Folate deficiency, 19, 194–195
Fluid requirements, for exercising dog, 54
Folate additive, defined, 58
Food allergy. See Cutaneous adverse food reaction (CAFR)
Food and Drug Administration (FDA), 58–59, 105
Food aversion, in cats with hepatic lipidosis, 240
Food hypersensitivity, 203, 206
Food immunosensitivity, 182–183
Food labels
organic designations, 97
termology, 97
USDA seal, 97
Food Processor (software), 20
Food puzzles, 121
Food responsive diarrhea, 200–201
Food sensitivity, 200–201
Food puzzles, 121
Food responsive diarrhea, 200–201
Food sensitivity, 200–201, 201t
Formulas, commercial, 83
Fractures
calcium deficiency and, 132, 132f–133f
metabolizable energy calculation, 42
Fragmented coronoid process (FCP), 141–142
Free-choice feeding, 80
Free radicals, arginine effect on, 186
Free-Choice Feeding, 80
Free radicals, arginine effect on, 186
Frequency of feeding, for flatulence prevention, 205
Fructans, 177t
Fructooligosaccharides (FOSs), 343
GAGPS (glycosaminoglycan polysulfuric acid), 149
GAGs (glycosaminoglycans), 146
Gas
flatulence, 206–207
intestinal transit, 205–206
Gastrocutaneous fistulas, 345
Gastrointestinal disease, 175–208
Gastrointestinal disorders, 175–208
Gastrointestinal tract
ulcer, 178–183
Gastrointestinal tract
ulcer, 178–183
Gastroesophageal segment relaxations, 193
Gastroesophageal reflux, 193
Gastroesophageal segment relaxations, 192–193
Gastrointestinal disease, 175–208
 acute disease, 183–188
 benefits of luminal nutrition in, 184–187
 feeding recommendations, 187–188, 188t
 inflammation and, 185–186
 intestinal permeability, 186–187
 intestinal recovery and adaptation, 185
 withholding food, 183–184
 chronic disease, 188–202
 adverse food reactions, 200–201, 201t
 esophageal disease, 192–193
 inflammatory bowel disease, 193–199
 periodontal disease, 188–192
 protein-losing enteropathies, 200, 200t
 short bowel syndrome, 201–202
 small intestinal disease, 193–202
 immune response to dietary antigens, 180–183
 food immunogenicity, 182–183
 immunological basis for, 180–181
 loss of tolerance, 181–182
 key dietary variables, 175–180
 fat, 176–177
 fiber, 177–180, 177t–178t, 180t
 glutamine, 176
 protein, 175
 large intestinal disease, 202–207
 acute colitis, 202–203
 chronic colitis, 203–204
 constipation, 204–205
 gas and flatulence, 205–207
 idiopathic large bowel diarrhea, 204
 megacolon, 204–205
 Gastrojejunostomy tubes, 335–336
 Gastrostomy feeding
 in cancer, 318
 in hepatic lipidosis, 239
 in pancreatitis, 225
 tubes
 complications of, 334
 disadvantages of, 334
 low profile, 334f
 overview, 334–335, 334f
 placement of, 334
 Generally recognized as safe (GRAS), 58–60
 Generic dog food dermatosis, 161, 161f
 Gestation
 energy requirements for, 40
 feeding guidelines for, 81–83
 assessment, 83
 cats, 81–82
 dogs, 82–83
 supplementation, 83
 Giant migrating contractions, of large intestine, 203
 Gingival stimulation, 190–191
 Gingivitis, 188–192
 Glomerular disease, 262–263
 Glucagon-like peptide-1 (GLP-1), 176–177
 Glucagon-like peptide-2 (GLP-2), 185
 Glucagon-like peptide-1 (GLP-1), 176–177
 Glucagon-like peptide-2 (GLP-2), 185
 Glucose
 given during exercise, 55
 intolerance in liver disease, 236
 Glutathione
 effect on intestinal inflammation, 185
 in enteral feeding, 342
 gastrointestinal health and, 176
 for inflammatory bowel disease therapy, 196
 supplementation in cancer, 320–321
 Glutathione peroxidase, 195
 Glycogen
depletion in liver disease, 235
use during exercise, 50–51
Index

Glycosaminoglycan polysulphuric acid (GAGPS), 149
Glycosaminoglycans (GAGs), 146, 148
“Gonto Protocol,” 263
Good manufacturing practices (GMPs), 62, 65
GRAS (generally recognized as safe), 58–60
Green-lipped mussel (GLM), 149, 150t

Hair
protein deficiency and, 157–158
vitamin A deficiency and, 161
HCS (hepatocutaneous syndrome), 162–166
HDL (high-density lipoprotein), 294
Heat increment, 25
Hemicelluloses, 177t
Hepatic encephalopathy, 243–246
antimicrobials, 246
nonabsorbable disaccharides, 246
overview, 243–245
protein, 245–246
malnutrition in, 238
metabolic alterations in liver failure, 235–238, 236f
carbohydrates, 235–236
lips, 237
proteins and amino acids, 236–237
vitamins and minerals, 237–238
Hepatocutaneous syndrome (HCS), 162–166
Hepatocytes, 235
Hexametaphosphate (HMP), 190
Hip dysplasia, 144–145, 144f
Histidine deficiency, 15
HMP (hexametaphosphate), 190
HOD (hypertrophic osteodystrophy), 144–145, 144f
Home-prepared diets, 98–104
case study, 99, 100f
for chronic hepatitis, 246–247
for chronic kidney disease, 259–260
for copper hepatotoxicity, 242
custom-formulated, 103–104
diet trials, 168
for feline idiopathic hypercalcemia, 297
for flatulence prevention, 206–207
data on, 98
patient management, 101–104
carbohydrates, 102
fatty acids, 102
general considerations, 103–104
patient assessment, 104
protein and amino acids, 101–102
vitamin and mineral supplements, 102–103
reasons for owner use of, 98
for the short-term management of acute gastroenteritis in dogs and cats, 187–188, 188f
Hormone-sensitive lipase, 294
Housekeeper contractions, intestinal, 183
Hydration, for exercising dog, 54
Hydrogenated coconut oil, 341–342
Hydrogen sulfide, 206
Hydrolyzed protein diets
for chronic colitis, 204
in elimination diet trial, 168
for flatulence prevention, 206–207
for short bowel syndrome, 202
Hypercarnitinaemia, 270
Hypercalcemia
calcium oxalate uroliths with, 270
feline idiopathic, 297
Hypercalciumia, 270
Hypercholesterolemia
in hyperlipidemia, 294–295
in obstruction to bile flow, 237
Hyperglycaemia in liver disease, 236, 236f
Hyperglycemias
in liver disease, 236f
as parenteral nutrition complication, 367
Hyperinsulinemia, in liver disease, 236
Hyperkalemia
in chronic kidney disease, 255–256
Hyperlipidemia, 294–296
classification and etiology, 294
clinical signs and diagnosis, 294
management and assessment, 294–296
as pancreatitis risk factor, 223
as parenteral nutrition complication, 367–368
Hyperoxaluria, 271
Hyperparathyroidism
in chronic kidney disease, 253–254
nutritional secondary, 99, 100f
skeletal effects, 131–134, 132f–133f
Hypertension
in cats, 303
in chronic kidney disease, 254–255
white coat, 303
Hyperthyroidism, 296–297
Hypertriglyceridemia, in hyperlipidemia, 294–295
Hypertrrophic cardiomyopathy, 302–303
Hypertrrophic osteodystrophy (HOD), 144–145, 144f
Hypervitaminosis A, 138–139
Hypovitaminosis C, 144–145
Hypothyroidism, 296–297
Hypophosphatemia, 134, 134f
Hypothyroidism, 296
Hypovitaminosis C, 144–145
Hypovitaminosis D, 134–135
Index

IBD. See Inflammatory bowel disease
IBIDS (International Bibliographic Information on Dietary Supplements) database, 64
ICAM-1, 185
IDDM (insulin-dependent diabetes mellitus), 289, 291, 293
Idiopathic cystitis, 282–283
Idiopathic large bowel diarrhea, 204
IgE mediated type 1 hypersensitivity, 166
IGF-1. See Insulin-like growth factor
Immune response, age-related changes in, 87–88
Immunity. See Intestinal immunity
Immunogenicity, food, 182–183
Immunity, effect of luminal nutrients on, 185–186
Indirect respiratory calorimetry, 31–33
Incongruities of the elbow joint, 141–142
Inflammaging, 87–88
Inflammation
effect of luminal nutrients on, 185–186
Infant nutrition, 111
Infl ammatory bowel disease (IBD), 193–199
diagnosis, 193, 196
etiology, 193–194
management recommendations, 199
nutritional derangements in chronic IBD
antioxidants, 195
hypomagnesium, 194
iron-deficiency anemia, 194
protein-energy malnutrition, 194
vitamin B12 and folate deficiency, 194–195
vitamin K deficiency, 195
zinc deficiency, 195
nutritional strategies for therapy, 196–199
antioxidants, 197
arginine and nitric oxide, 196–197
dietary fat, 197–198
glutamine, 196
polyunsaturated fatty acids (PUFAs), 198–199
pre- and probiotics, 196
pathogens, dietary antigens and, 195–196
Information sources, on dietary supplements, 66, 66t
Ingredient declaration, food label, 70–71
Insulin, 289–293
Insulin-dependent diabetes mellitus (IDDM), 289, 291, 293
Insulin-like growth factor (IGF-I)
bone growth and, 128
excessive food intake or fasting influence on, 147, 148
location of synthesis and secretion, 185
Integument, age-related changes in, 87
International Bibliographic Information on Dietary Supplements (IBIDS) database, 64
International Organization for Standardization (ISO), 364
International Renal Interest Society (IRIS), 252
International Small Animal Cardiac Health Council (ISACHC), 302
Intestinal flora, effect of fiber on, 180
Intestinal gas, 205–206
Intestinal immunity
effect of butyrate on, 179–180
response to dietary antigens, 180–183
Intestinal permeability, effect of feeding on, 186–187
Intrinsic factor, 228
Inulin, 177t
Iodine deficiency, 17–18
IRIS (International Renal Interest Society), 252
Iron deficiency, 17, 194
ISACHC (International Small Animal Cardiac Health Council), 302
ISO (International Organization for Standardization), 364
Isoleucine deficiency, 15
Isotretinoin, 169
Jejunal feeding tubes, 335–336
Jejunostomy feeding tube in pancreatitis, 225–226
Joule, 23
Kaliuresis, 272
Kidney disease, 251–263
acute renal failure (ARF), 260–262
chronic, nutritional therapy for,
251–260
acid-base balance, 256
administration of therapy, 259
antioxidants, 257
clinical efficacy, 258–259
concurrent diseases, 259–260
electrolytes, 254–256
energy, 251–252
fiber, 256–257
long-chain omega-3 fatty acids, 256
monitoring management, 260
nutrients that target endothelium, 258
phosphate, 253–254
potassium, 255–256
protein, 252–253
sodium, 254–255
water, 251
water, 251–260
Fanconi Syndrome, 263
glomerular disease, 262–263
metabolizable energy calculation in renal failure, 42
Kilocalorie (kcal), 23
Kittens
energy requirements for growth, 40
feeding guidelines for orphans, 83–84
from weaning to adult, 84–85
Kleiber’s equation, 34
Label, pet food
“3% rule,” 70
“25% rule,” 70
“95% rule,” 69
“100% rule,” 69
back panel, 70
calorie content, 71–72
company contact information, 71
estimating calorie content, 72
feed directions/guidelines, 71
front display panel, 69–70
guaranteed analysis, 71
ingredient declaration, 70–71
nutrient levels, 71
nutritional adequacy, 70
product name, 69–70
regulatory oversight of, 69
Labradorescent, copper hepatotoxicity, 241, 241f
Lactase deficiency, 184, 201t
Lactation
energy requirements for, 40–41
feeding guidelines, 81–83
assessment, 83
cats, 81–82
dogs, 82–83
supplementation, 83
Lactic acidosis, 51
Lactose intolerance, 184
Lactulose, for hepatic encephalopathy, 246
LAD (lethal acrodermatitis), 160–161
Large intestinal disease, 202–207
acute colitis, 202–203
chronic colitis, 203–204
constipation, 204–205
gas and flatulence, 205–207
idiopathic large bowel diarrhea, 204
megacolon, 204–205
L-carnitine, as weight reduction aid, 118t
Linoleic acid
deficiency, 16, 158
described, 12
in home-prepared diets, 102
Liver.

Liquid diets for enteral nutrition, 338, 339t–341t, 341–342
Lipoprotein lipase, 237, 294

Lipids
heat equivalents, 32
metabolic alterations in liver disease, 237
respiratory quotient, 32

Lipoprotein lipase, 237, 294
Liquid diets for enteral nutrition, 338, 339t–341t, 341–342
Liver. See also Hepatobiliary diseases hepatocutaneous syndrome (HCS), 162–166
ultrasound “honeycomb” pattern, 165
Long chain omega-3 fatty acids. See also Omega-3 fatty acids in chronic kidney disease, 256
for glomerular disease, 262
Long-distance submaximal aerobic exercise, nutritional and energy requirements for, 53
Longevity decrease with obesity, 111
Low carbohydrate diet, 117
Low density lipoprotein (LDL), 294
Lower urinary tract disease, 269–283
idiopathic cystitis, 282–283
incidence of, 269
matrix-crystalline urethral plugs, 282, 282f

Lymphocytic-plasmacytic inflammation, 197
Lymphangiectasia, 197
Lymphangiectasia, intestinal, 203
Lysine deficiency, 15

Macrominerals
deficiency, 16–17
role in nutrition, 13

Magnesium
in bone, 126, 126t–127t
in calcium oxalate urolithiasis, 273
in congestive heart failure, 307
deficiency, 16, 194
role in bone formation, 128–129
Magnesium ammonium phosphate hexahydrate. See Struvite uroliths
Mane Coon, hypertrophic cardiomyopathy in, 302
Maintenance energy requirement (MER) for adult cats, 37t, 38f–39f
for adult dogs, 35t–36t, 38f–39f
calculating, 34–38, 35t–37t, 38f–39f
in cancer, 317
defined, 24
equation, 34
Malnutrition
in liver disease, 238
in uremia, 260–261
Manganese deficiency, 17
Matrix-crystalline urethral plugs, 282, 282f
Matrix metalloproteinases (MMPs), 146
MCTs. See Medium-chain triglycerides
Meal-induced thermogenesis. See Heat increment
Medium-chain triglycerides (MCTs)
in exocrine pancreatic insufficiency, 229
in liquid diets, 341–342
Megacolon, 192–193
Megacolon, 204–205
Megaspheres, 192
Melamine, 12
Melanoids, 183
MEN (metabolic epidermal necrosis), 162
MER. See Maintenance energy requirement
Metabolic acidosis
as calcium oxalate urolith risk factor, 271
in chronic kidney disease, 256
Metabolic epidermal necrosis (MEN), 162
Metabolizable energy calculating
in disease state, 42
for growth, 38–40
at maintenance, 34, 37
for pregnancy and lactation, 40–41
calculating content of diet, 26–31
crude fiber and, 30–31
estimating intake from diet record, 26
requirements of dogs undertaking different types of activity, 50f
requirements of exercising dogs, 47, 48t
Metaphyseal osteopathy, 144
Methionine production, 205
Methionine
deficiency, 15
excess, 21
as sparing nutrient, 10
Methocarbamol, for vomiting, 240
Microminerals
deficiency, 17–18
role in nutrition, 13
Migrating motor complexes, intestinal, 183
Milk-based diet, for hepatic encephalopathy, 245
Milk production. See Lactation
Milk replacer, commercial, 83
Milk thistle extract, for copper hepatotoxicity, 242

Minerals
abnormalities in liver disease, 237–238
in bone, 126–127, 126t–127t
deficiency, 16–18
macrominerals, 16–17
microminerals, 16–17
in diabetes mellitus, 293
for exercising dogs, 55
macrominerals, 13
microminerals, 13
in parenteral nutrition, 361
role in nutrition, 13
supplements in home-prepared diets, 102–103

Miniature Schnauzer hypercalciuria in, 270–272
hyperlipidemia in, 223, 294
vitamin A responsive skin disease, 169
Minimal requirement, defined, 21
Mitochondrial cofactors, for canine cognitive dysfunction disorder, 89
Mixed tocopherols, 14
MMPS (matrix metalloproteinases), 146
Modified Atwater equation, 30
Moist food, 95–96
Monoacylglycerides, intestinal absorption of, 176
Monomeric formulations, 341
Motility disorders, esophageal, 192
Multilumen polyurethane catheters, 358, 358f
Muscle fiber types, 51
Musculoskeletal system, age-related changes in, 87
N-(2-mercaptopyrrolyl)-glycine (2-MPG), 280–281
N-3 fatty acids. See also Omega-3 fatty acids
in congestive heart failure, 306–307
sources of, 12
supplementation for older pets, 89
supplementation in cancer, 322
N-6 to n-3 ratio, for inflammatory bowel disease therapy, 199
NASC (National Animal Supplement Council), 58, 62
Nasoepteral feeding tubes overview, 332
placement of, 332f
Nasoesophageal feeding in cancer, 318
in hepatic lipidosis, 239–240
in pancreatitis, 226

Index
Index

skeletal growth and development, role of nutrition, 129–139
calcium deficiency, 129–134, 130t, 131f–133f, 132t
calcium excess, 135–137, 136f, 137f, 138f
ergy, 129
phosphorus deficiency, 134, 134f
trace mineral deficiency, 135
vitamin A excess, 138–139
vitamin D deficiency, 134–135, 135t
vitamin D excess, 137–138
Osmotic diarrhea, 184
Osteoarthritis
causes of, 147
dietary support treatment of, 146–151
causative role of nutrition, 147
therapeutic role of nutrition, 147–151, 150t
elbow, 141–142, 141f
hip, 142–144
Osteoblasts, 125
Osteochondritis dissecans (OCD) of the medial humeral condyle, 141–142
Osteoelasts, 125
Overweightedness. See also Weight loss plan
health consequences of, 110–111, 144
hip dysplasia and, 144
increasing awareness of, 111–113
prevalence of, 109–110
Oxalic acid, 271–274
Oxidative stress, in chronic kidney disease, 254
Parathyroid hormone (PTH), 127–129, 137, 253
Parenteral nutrition, 353–370
in acute renal failure, 261–262
administration of, 365–366
algorithm for method choice, 356f
in cancer, 318–319
catheter selection and placement, 357–358, 358f
in chronic hepatitis, 246
common solutions and supplements, 359t
complications, 366–370
mechanical, 368–369, 369f
metabolic, 367–368
septic, 369–370
components of, 358–363
carbohydrates, 360–361
electrolytes, 361
fat, 360
protein, 358–360
trace minerals, 361
vitamins, 361, 363
compounding, 363–365, 364f, 365f
discontinuing, 370
energy requirements, 363
formulation calculations, 362t, 363
goal rate, 366
history, 353
initiating, 365–366
monitoring guidelines, 366, 366t
omenclature, 357
nutritional assessment, 354–356, 355t
in pancreatitis, 226
patient selection, 354–356
route of administration, 357
worksheet, 362
PDCAAS (protein digestibility corrected amino acid score), 12
Pectins, 177t
PEG (percutaneous endoscopic gastrostomy) tube, in pancreatitis, 225
Penicillamine, for copper hepatotoxicity, 242
Peptide YY (NPYY), 176
PER (protein efficiency ratio), 12
Percutaneous endoscopic gastrostomy (PEG) tube, in pancreatitis, 225
Performance
energy requirements for, 48–50
nutritional recommendations, 52–55
adequate intakes, 52t
antioxidants, 54–55
ergogenic nutrients, 55
fluids and electrolytes, 54
for long-distance submaximal aerobic exercise, 53
for short-distance supramaximal anaerobic exercise, 53–54
time of feeding, 55
vitamins and minerals, 55
Perineal urethrostomy, 282
Periodontal disease
dental diets for, 190
diet influence on saliva and flora, 191
in feral and wild animals, 189
gingival stimulation, effect of, 190–191
overview, 188–189
prevalence of, 188
protective effect of chewing activities, 189–190
recommendations, 191–192
Periosteal growth, 125
Peripheral parenteral nutrition (PPN), 261–262, 357
Perritosis, 345
Peroxisome proliferator-activated receptors (PPARs), 198
Peroxynitrite, 186
Peyer’s patches, 180
Pharaoh Hound, zinc responsive dermatosis in, 160
Pharyngostomy feeding
in cancer, 318
overview, 332
Phenylalanine deficiency, 15
Phosphorus
in bone, 126–127, 126–127t
in calcium oxalate urolithiasis, 273
deficiency, 16, 134, 134f
restriction
in acute renal failure, 261
in chronic kidney disease, 253–254
“Pickwickian Syndrome,” 110
Plaque, 188–192
Polydipsia, in chronic kidney disease, 251
Polymeric formulations, 341
Polyunsaturated fatty acids (PUFAs)
deficiencies and skin diseases, 158
in inflammatory bowel disease therapy, 198–199
in orthopedic diseases, 149
Pomeranian, urate uroliths in, 278f
Portion-controlled feeding, 80, 84
Portosystemic shunts, 243–246, 243f, 244f
antimicrobials, 246
nonabsorbable disaccharides, 246
overview, 243–245
protein, 245–246
Potassium
in chronic kidney disease, 255–256
in congestive heart failure, 307
deficiency, 17
depletion in liver disease, 238
in hepatic lipodosis, 240
restriction in acute renal failure, 261
supplementation in chronic kidney disease, 255
Potassium citrate
  for calcium oxalate urolith prevention, 273
  for urate uroliths, 279
Poultry by-products, 71
Poultry meal, 71
PPN (peripheral parenteral nutrition), 261–262, 357
Prebiotics, 102, 196
Prebiosis, 180
PPARS (peroxisome proliferator-activated receptors), 198
Probiotics, 196
for inflammatory bowel disease, 196
quality control for veterinary products, 196
Product brochures and guides, 72–74
Product name, on food label, 69–70
Protein. See also Amino acids
  assessment of, 11–12
  in calcium oxalate urolithiasis, 273
  in cancer diet, 319–320, 322
  in chronic kidney disease management, 252–253
deficiency, 14–16
  signs, 14
  skin disease and, 157–158, 158t
  testing, 14–16
  in diabetes mellitus, 292–293
digestibility, 175
  in elimination diet trial, 168
gastrointestinal tract interaction, 175
  heat equivalents, 32
  heat treatment during food manufacturing, 182–183
  hepatic encephalopathy management and, 245–246
  in hepatic lipodosis, 240
  in home-prepared diets, 101–102
  hormone stimulation by, 175
  hydrolyzed, 168
  immunogenicity of food, 182–183
  in liver disease, 236–237
  in parenteral nutrition, 358–360
  quality, 12
  requirements
    in cats, 75
    in older pets, 88
  respiratory quotient, 32
  restriction
    for chronic kidney disease, 252–253
    for congestive heart failure, 306
    in glomerular disease, 262
    in older pets, 88
    role in diet, 11
Protein digestibility corrected amino acid score (PDCAAS), 12
Protein-energy malnutrition in inflammatory bowel disease, 194
Protein hydrolysate diets, for inflammatory bowel disease, 195–196
Protein-losing enteropathies, 200
Protein-losing nephropathies, 262
Proteinuria, 262–263
Prophylaxis strategies, 196
for idiopathic large bowel diarrhea, 204
  as “mixed” fiber, 13, 293
  for short bowel syndrome, 202
Psyllium
  for calcific urolith prevention, 279
  for calcium oxalate urolith prevention, 279
  for idiopathic large bowel diarrhea, 204
  as “mixed” fiber, 13, 293
  for short bowel syndrome, 202
Pyridoxine deficiency, 19, 162
Pyruvate, as weight reduction aid, 118t
Radius curvus syndrome, 137, 138f
Ragdoll cat, hypertrophic cardiomyopathy in, 302
Raw diet
  in cancer, 324
  commercial, 96, 104–105
  concerns with, 104–105
  overview, 104–105
Recommended allowance, defined, 21
Refeeding syndrome, 345–346, 368
Renal disease. See Kidney disease
Renal system, age-related changes in, 87
Renal disease, metabolizable energy calculation and, 42
Respiratory disease, metabolizable energy calculation and, 42
Respiratory quotient, 32–33
Resting energy, 25
Resting energy expenditure
  calculating, 34
  defined, 25
  equation, 34
Resting energy requirement (RER)
  for adult cats, 37t
  for adult dogs, 35t–36t
  calculating
    for parenteral nutrition, 363
    for weight loss program, 117
    in cancer, 317
  Resting metabolic rate, defined, 25
Retinoids, 169
Revenue
  from food sales, 3
  from nutritional advice, 5–7
for healthy patients, 6
for unhealthy patients, 6–7
strategies to increase sales, 3–5
  recommending effective therapeutic food, 3–5
  recommending nutraceuticals and dietary supplements, 5
  recommending therapeutic treats, 5
Riboflavin deficiency, 19, 162
Rice, in acute gastroenteritis diet, 187–188
Rickets
  hypophosphatemic, 134, 134f
  vitamin D deficiency, 135
S-adenosylmethionine (SAMe)
  for copper hepatotoxicity, 242
  supplementation for hepatic lipodosis, 241
Safe upper limit, defined, 21
Saliva, influence of diet on, 191
Salmonella infections, with raw food feeding, 104–105
SBS. See Short bowel syndrome
SCFAs (short-chain volatile fatty acids), 179
Scottish Terrier, hepatocutaneous syndrome (HCS) in, 164
Scurvy, 144
Secondary hyperparathyroidism, in chronic kidney disease, 253–254
Secretion, 221
Selenium deficiency, 17
Semi-moist food, described, 96
Senior dogs and cats
  feeding recommendations, 89–90
  nutritional requirements, 88–89
    energy, 88
    fat, 89
    protein, 88–89
  physiological changes in aging, 86–88
    behavior, 88
    digestion and absorption, 87
    energy requirement, 86–87
    immune response, 87–88
    integument and musculoskeletal system, 87
    renal system, 87
    sensory, 88
    weight loss, unintended, 90
Sensory systems, age-related changes in, 88
Sepsis
  complications of parenteral nutrition, 369–370
  metabolizable energy calculation, 42
Shetland Sheepdog
  hepatocutaneous syndrome (HCS) in, 164
  hyperlipidemia in, 223
Index

Short bowel syndrome (SBS) feeding recommendations, 201–202 intestinal adaptation, 201 pathophysiology, 201
Short-chain volatile fatty acids (SCFAs), 179
Urolithiasis, 269–282
  calcium oxalate, 270–274, 270f
  compound uroliths, 281, 281f
  cystine, 280–281, 280f–281f
  struvite, 274–276, 274f–275f
  surgical and minimally invasive management of, 282
  urate, 276–279, 277f–279f
  xanthine, 279f, 280
USDA Nutrient Database for Standard Reference, 20, 27, 80
USDA seal, 97
USP (United States Pharmacopeia), 364
Valine deficiency, 16
Vegetable-based diets, for hepatic encephalopathy, 245
Very-low-density lipoprotein (VLDL), 294–295
VFs (volatile fatty acids), 179
Vitamin(s)
  deficiency, 18–20
  fat soluble, 18
  in liver disease, 237
  water soluble, 18–20
  in diabetes mellitus, 293
  for exercising dogs, 55
  for parenteral nutrition, 359t, 361, 363
  role in nutrition, 13–14
  fat soluble, 13–14
  water soluble, 13
  supplements in home-prepared diets, 102–103
Vitamin A
  cat requirement for, 75
  cautionary use in liver disease, 237
  converting units of, 73–74
  deficiency, 18, 158t, 161
  excess, 14, 21
  orthopedic disease and, 138–139
  production from carotenoids, 14
  production in the dog, 76
  responsive skin disease, 169
  skin disease and, 158t, 161
Vitamin B1 deficiency, 18–19
Vitamin B2 deficiency, 19
Vitamin B3 deficiency, 19
Vitamin B5 deficiency, 19
Vitamin B6
  in calcium oxalate urolithiasis, 274
deficiency, 19
Vitamin B7 deficiency, 19
Vitamin B9 deficiency, 19
Vitamin B12
  decrease in hepatic lipoidosis, 240
deficiency, 19

Vitamin C
  cat requirement for, 75
  cautionary use in liver disease, 237
  converting units of, 73–74
  deficiency, 18, 158t, 161
  excess, 14, 21
  orthopedic disease and, 138–139
  production from carotenoids, 14
  production in the dog, 76
  responsive skin disease, 169
  skin disease and, 158t, 161

Vitamin D
  cat requirement for, 75
  chronic intoxication, 138
  deficiency, 18, 134–135
dog requirement for, 76
  excess, 21, 137–138
  inborn errors of metabolism, 135
  metabolites, 128t
  orthopedic disease and, 134–135
  recommendations for growing dogs, 135t
  sources, 14

Vitamin D-binding proteins, 135
Vitamin E
  for copper hepatotoxicity, 242
deficiency, 18, 158t, 161–162
  for liver disease management, 237
  skin diseases and, 158t, 161–162
  sources, 14
  supplementation
    in chronic kidney disease, 257
    in hepatic lipoidosis, 241
    for older pets, 89

Vitamin H deficiency, 19
Vitamin K
  deficiency, 18, 195
  in liver disease, 237
  sources, 13–14

VLDL (very-low-density lipoprotein), 294–295
Volatile fatty acids (VFAs), 179
Vomiting
  in enterally fed patients, 346
  metoclopramide for, 240
  withholding food to reduce risk of, 183–184

Wasting in uremia, 261
Water
  in chronic kidney disease, 251
  in diabetes mellitus, 289
  in Fanconi Syndrome, 263

Weight gain. See also Obesity; Overweightness
  preventing after neutering, 84–85
  risk factors for, 112–113

Weight loss
  in cancer, 315–316, 317f
  unintended in older pets, 90

Weight loss plan
  adjustment, 120–121
  assessment, 119–120
  safety and efficacy, 120
  time to achieve goal, 119b
  formulation, 116–119, 117b, 118t–119t
  design considerations, 119t
  dietary considerations, 117–118
  exercise, 119
  nutrients and dietary supplements, 118t
  steps, 117b
  tailoring program to patient, 119
  multi-pet households, 121
  troubleshooting tips, 121t

West Highland White Terrier
  copper hepatotoxicity in, 241–242
  hepatocutaneous syndrome (HCS) in, 164

Wheat bran fiber, 178, 202
White Bull Terriers, lethal acrodermatitis in, 160–161
Whitlockite, 126–127, 127t
Withholding food for acute nonspecific gastroenteritis, 183–184

Xanthine uroliths, 279f, 280
Xanthomas, cutaneous, 169
X-linked hereditary nephritis, 262

Zinc
  deficiency
    in inflammatory bowel disease, 195
    in liver disease, 237–238
    skin diseases and, 158t, 159–161, 159f
  symptoms, 17
  supplementation
    in acute gastroenteritis, 184–185
    for copper hepatotoxicity, 242
    for hepatic encephalopathy, 246
    for skin disease, 171

Zinc responsive dermatitis, 159–160